Perifosine

N/A

Report date: 2026/02/14 20:00:22
NME

Base Information

Drug NamePerifosine
Drug Alias Name哌立福辛perifosina哌立福新Perifosinperifosinum +[10] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPI3-kinase class I inhibitors
TargetsPI3-kinase class I
Therapy Area/IndicationsSkin MelanomaSolid tumoursMyelodysplastic Syndromes +[40] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaCanadaUnited States +[9] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesCOSCIENS Biopharma Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesDana-Farber Cancer InstituteNational Cancer InstituteUniversity Of Wisconsin-Madison +[6] 
Active IndicationsN/A
Inactive IndicationsSkin MelanomaSolid tumoursMyelodysplastic Syndromes +[40] 

Other Information

ATC CodeN/A
Related LinksWikipedia